Capone M, et al. - In this retrospective analysis, researchers investigated the role of neutrophil-to-lymphocyte ratio (NLR) derived (d) NLR in the prediction of response to treatment with nivolumab in 97 consecutive patients with stage IV melanoma. They observed an association of both NLR and dNLR with improved survival when baseline levels were lower than cut-off values. They suggested that NLR and dNLR could be used to aid prediction of response to immunotherapy in patients with advanced melanoma. These were recognized as simple, inexpensive and readily available biomarkers.